Dr. Tyler Francis Stewart, MD

Dr. Stewart practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Stewart's NPI, 1699110676, was assigned on May 6, 2013. Dr. Stewart graduated from The Robert Larner, M.D. College of Medicine in 2013. Dr. Stewart's California license number on file is A163409.

Dr. Stewart's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Stewart's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Stewart is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Stewart to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Stewart practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Stewart's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Stewart is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Stewart's licenses on file in 3 states: California, Connecticut and Texas.

Dmand AI lists chronic anemia, deep vein thrombosis (DVT) and prostate cancer among the conditions Dr. Stewart treats.

CMS data shows 990 Medicare services from Dr. Stewart across 6 procedure codes in 2024, for 216 Medicare patients. Medicare paid $78,815 for them.

CMS counts 216 Medicare patients who saw Dr. Stewart in 2024. The largest group is 65 to 74, with 97 patients. 75% of them have cancer, and 74% have high blood pressure. 20% are also on Medicaid. Their average risk score is 2.30, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Stewart's median patient age at 74, with 15% women.

In 2024, Dr. Stewart wrote 734 Medicare Part D claims for 119 patients. 67% of them were for generic drugs. CMS names the drug for 580 of them, across 18 drugs with 11 or more claims each, at $2,476,308 in total drug cost. In 2023, CMS named 586 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Stewart for performance year 2024, reported as part of a group. Dr. Stewart accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Stewart as offering telehealth.

Dmand AI links 58 papers to Dr. Stewart, published from 2016 to 2025. 2021 was the busiest year, with 17. The most frequent topics are Urinary Bladder Neoplasms, Carcinoma, Transitional Cell and Immune Checkpoint Inhibitors. Dr. Stewart has published most often in Clin Genitourin Cancer. Dr. Stewart's most frequent co-authors are Rana Ramzi McKay, MD, Brent Shane Rose, MD and Alexandra Drakaki, MD.

Dmand AI links Dr. Stewart to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms and Carcinoma in Situ.

CMS Open Payments shows 74 general payments to Dr. Stewart from 26 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 79% of the total. Seagen Inc. paid the most, $7,820.

Dr. Stewart graduated from The Robert Larner, M.D. College of Medicine in 2013.

Dr. Stewart is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.